NEDD4 binding protein 2 like 2Genealiases: 92M18.3 · CG005 · CG016 · PFAAP5
Q-omics provides the consensus-scored N4BP2L2 profile across patient tissues and cancer cell-line models. N4BP2L2 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, N4BP2L2 is differentially expressed in 10, with the highest sampling consensus in LUSC. Additionally, N4BP2L2 RNA expression shows 21,628 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight CESC, LUSC, and UVM as cancer lineages where N4BP2L2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for N4BP2L2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes N4BP2L2 survival associations across molecular data types. N4BP2L2 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible N4BP2L2 RNA expression–survival associations across cancer types. High N4BP2L2 expression shows unfavorable associations in CESC, UVM, ACC and READ, but favorable associations in SKCM and MESO. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for N4BP2L2 RNA expression.
This table summarizes N4BP2L2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 2. The strongest signals are observed in LUSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for N4BP2L2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. N4BP2L2 shows lower tumor expression in LUSC, KICH, LUAD, UCEC and BRCA and higher tumor expression in LIHC. The LUSC box plot shows higher N4BP2L2 RNA expression in normal versus tumor tissue (log2 FC = −1.298, t-test p < 0.001).
This table shows molecular features associated with N4BP2L2 in patient tissues and cancer cell lines. In patient samples, N4BP2L2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, N4BP2L2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BONE and UPPER_AERODIGESTIVE_TRACT.
